From: How innovation can be defined, evaluated and rewarded in health technology assessment
NICE (England and Wales) | CIPM & AEMPS (Spain) (‡) | AIFA (Italy) | HAS (France) | NIPH (Japan) | |
---|---|---|---|---|---|
All HTA | Medicines | Medicines | Medicines | All HTA | |
Attributes related to therapeutic added value of technology, compared to relevant comparator | |||||
Therapeutic benefit | ✓ | ✓ | ✓ (I) | ✓(I) | ✓(I) |
Attributes related to step-change | |||||
Step-change in the management of the condition | ✓(I) | ✗ | ✗ | ✗ | ✓(I) |
Disruptiveness | ✗ | ✗ | ✗ | ✓ | ✗ |
Breakthrough status | ✗ | ✗ | ✗ | ✗ | ✗ |
Demonstratable and distinctive benefit | ✓(I) | ✗ | ✓ (I) | ✗ | ✗ |
Attributes related to the underlying health condition of the patients & current care | |||||
Severity of underlying disease | ✗ | ✓ | ✗ | ✓(I) | ✗ |
Impact on the health of the population | ✓ | ✗ | ✓ | ✓(I) | ✓ |
Availability of existing intervention | ✓ | ✓ | ✓ | ✓ | ✓ |
Unmet need | ✓ | ✓ | ✓(I) | ✓ | ✓ |
Attributes related to safety | |||||
Safety | ✓ | ✓ | ✓ | ✓ | ✓(I) |
Attributes related to convenience | |||||
Administration | ✗ | ✓ | ✓ | ✓ | ✓(I) |
Patient usefulness (i.e. convenience) | ✓ | ✗ | ✓ | ✓ | ✓(I) |
Carer usefulness (i.e. convenience) | ✗ | ✗ | ✗ | ✗ | ✗ |
Attributes related to economic impact | |||||
Cost or budget impact | ✓ | ✓ | ✓ | ✓ | ✓ |
Impact on non-healthcare resources and productivity benefits | ✗ | ✗ | ✗ | ✗ | ✗ |
Incremental cost-effectiveness ratio | ✓ | ✓ | ✓ | C | ✓ |
Attributes related to the evidence base | |||||
Strength of clinical evidence | ✓ | ✗ | ✓(I) | ✓ | ✓ |
Learning curve | ✗ | ✗ | ✗ | ✗ | ✗ |
Attributes related to R&D and impact on future innovation pipeline (dynamic effects) | |||||
Novelty | ✓(I) | ✗ | ✓ | ✗ | ✓ |
Spill-over effects | ✗ | ✗ | ✗ | ✗ | ✗ |
Real option value | ✗ | ✗ | ✗ | ✗ | ✗ |
References |